MATRIXYL-3000

Matrixyl-3000 is a two-peptide cosmetic blend developed by Sederma. The components are palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR), both matrikine peptides (extracellular-matrix-derived signaling fragments). The blend drives fibroblast collagen and glycosaminoglycan synthesis.

Different mechanisms targeting different wrinkle types. Argireline blocks SNARE-complex assembly at the neuromuscular junction, reducing dynamic expression-line wrinkles. Matrixyl-3000 stimulates dermal collagen and GAG synthesis, addressing static wrinkles from extracellular matrix loss. The two are complementary; many cosmetic formulations combine them.

Both target collagen synthesis but through different mechanisms. GHK-Cu (Gly-His-Lys + Cu²⁺) is the original copper-peptide first identified in the 1970s with documented collagen and elastin synthesis induction. Matrixyl-3000 uses two palmitoylated matrikine peptides for similar but distinct signaling. Both have evidence for wrinkle reduction; GHK-Cu has the longer evidence base.

The matrikine peptides mimic small fragments released during extracellular matrix turnover. These fragments signal to fibroblasts to upregulate new collagen (I, IV, VII), elastin, and glycosaminoglycan synthesis · the same response a fibroblast produces during normal wound healing. The palmitoyl moiety enables transdermal penetration.

Matrixyl-3000 is a cosmetic ingredient, not a drug. The FDA does not pre-approve cosmetic ingredients in the same way as drugs. Topical cosmetic use is widespread under existing FDA cosmetic-ingredient regulations.

Cosmetic formulations typically use 3-8% Matrixyl-3000. Robinson 2005 and Sederma supplier data describe measurable collagen-synthesis upregulation at these concentrations applied twice daily for 8-12 weeks.

Collagen synthesis is a slow process. Published trials report measurable improvements at 8-12 weeks of twice-daily topical application. Effects are dose- and duration-dependent.

Topical Matrixyl-3000 has no documented systemic absorption at cosmetic concentrations. The peptides are too large for significant transdermal absorption into the bloodstream. Rare mild local irritation is reported; no systemic side effects are described.